TY - CHAP M1 - Book, Section TI - Cutaneous Lymphomas & Leukemias A1 - Niklinska, Eva B. A1 - Zwerner, Jeffrey P. A1 - Zic, John A. A2 - Nouri, Keyvan Y1 - 2023 N1 - T2 - Skin Cancer: A Comprehensive Guide AB - SUMMARYCutaneous lymphomas are divided into T-cell and B-cell groups.The most common primary cutaneous T-cell lymphomas (CTCLs) are mycosis fungoides (MF) and its leukemic counterpart, Sézary syndrome (SS).MF pathogenesis evolves from resident memory T cells, which play a role in skin immune surveillance. SS pathogenesis evolves from central memory T cells, which contribute to circulating immune surveillance.Classic MF clinical manifestations include patches, plaques, tumors, and generalized erythroderma. SS clinical manifestations include generalized erythroderma and lymphadenopathy.Diagnosis is made with clinical and pathologic correlation via punch biopsies and, if indicated, flow cytometry of peripheral blood.Histopathology for MF and SS is notable for intermediate-sized dysplastic cerebriform T cells with enlarged hyperchromatic nuclei.When disease is limited to patches/plaques, therapy focuses on skin-directed treatments, whereas progression to tumors and erythroderma usually requires systemic therapy.The most common primary cutaneous B-cell lymphomas (CBCLs) are (1) primary cutaneous follicle center lymphoma (PCFCL); (2) primary cutaneous marginal zone B-cell lymphoma (PCMZL); and (3) primary cutaneous diffuse large B-cell lymphoma, leg type (PCDLBCL-LT).Clinical manifestations include the presence of purple to red nodules/papules on the head, neck, trunk, and legs. PCFCL and PCMZL have a more indolent disease course than PCDBCL-LT.Diagnosis is made through punch biopsy with histopathology and immunophenotyping to differentiate subtypes.Therapy includes radiotherapy, surgical excision, immunotherapy, and chemotherapy. SN - PB - McGraw-Hill Education CY - New York, NY Y2 - 2024/03/29 UR - dermatology.mhmedical.com/content.aspx?aid=1194724523 ER -